drugset

drugset / Trial / NCT00151333

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333 ↗

Phase 2 Completed 16 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.

Timeline

Start: 2005-02
Primary completion: 2005-04
Completion: 2005-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lecozotan	Small molecule	—	—

Indications